Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 3212345...102030...Last »

GSK’s Advair faces first direct competition

Teva Pharmaceutical Industries Ltd. launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.

Read More »

Trump Taps Congressman as Next ‘Drug Czar’

President Trump, hoping to take on the opioid epidemic sweeping parts of America, tapped U.S. Rep. Tom Marino to head up the Office of National Drug Control Policy.

Read More »

Changing the Learning Curve for Auto-Injection Therapy

As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.

Read More »

GSK’s new CEO gets short-term win from generic Advair delay

GlaxoSmithKline’s new CEO Emma Walmsley won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.

Read More »

U.S. lawmakers seek pricing info on DMD drug

Two U.S. lawmakers sent a letter to PTC Therapeutics Inc. seeking information about the drugmaker’s pricing strategy for its recently acquired muscle-wasting disorder drug.

Read More »

Harvoni Study: 97% of Hep C Patients Cured

Nearly all patients who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni were cured of the disease, according to PBM Prime Therapeutics.

Read More »

Republicans revamp Obamacare bill

Congressional Republicans recrafted their Obamacare replacement bill in hopes of satisfying critics.

Read More »

CytomX Surges as Bristol-Myers Squibb Signs Up for 8 More Projects

CytomX Therapeutics and Bristol-Myers Squibb are strengthening their relationship with the expansion of a 2014 collaboration agreement. The companies announced a plan to include up to eight additional targets, six in oncology and two in non-oncology areas, using CytomX’s proprietary Probody platform.

Read More »

Trump backs House Republican healthcare plan

President Donald Trump backed a draft U.S. House of Reps’ Republican bill to repeal and replace the Obamacare healthcare law that is open to negotiation.

Read More »

Special Feature – Agenda 2017: Growing Up

Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai

Read More »

2017 Annual Report: Top 10 Pipelines

There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.

Read More »

John Kamp: Industry peacekeeping with President Trump holds promise but portends danger

As a public official preparing for international negotiations, I was taught by the U.S. State Department to always know exactly what you want and what you’re willing to give up before sitting down with a skilled international trading partner. It looks like pharma representatives were well prepared recently when sitting down with the country’s new Negotiator-in-Chief, President Donald Trump, but they should be mindful that the other shoe has yet to drop.

Read More »

Launching a drug on all cylinders – winning with digital

“Failing to plan is planning to fail” states time management guru Alan Lakein. Nowhere does this axiom ring more true than in the tightly controlled world of Rx launches. Given the time and expense required to bring a prescription drug to market, coupled with its limited exclusive lifespan, we must maximize every moment from market conditioning to loss of exclusivity (LOE).

Read More »

Marathon pauses DMD drug launch

Marathon Pharmaceuticals is “pausing” the launch of its Duchenne muscular dystrophy drug after U.S. lawmakers questioned why the company priced it at $89,000 a year.

Read More »

Bayer’s Blood Thinner Effective For Artery Disease

Bayer’s best-selling blood-thinning drug Xarelto has also proved effective in preventing heart attacks and strokes in patients suffering from certain types of artery disease.

Read More »

Express Scripts: 2016 Rx drug spending slowed

Express Scripts Holding Co. – the largest U.S. pharmacy benefit manager – said prescription drug spending for its members slowed to less than 4 percent in 2016.

Read More »

Merck Reveals Recent U.S. Drug Price Increases

As drug pricing continues to be a concern for the public and the new presidential administration, Merck pulled back the curtain on its U.S. pricing practices.

Read More »

Tecentriq eroding Opdivo market share

Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb, but is making up lost ground.

Read More »

Merck CEO sees Keytruda in pole position in cancer race

Merck & Co.’s Keytruda cancer drug is in an increasingly strong position in a fiercely competitive market, the company’s CEO said.

Read More »

Regeneron CEO: Amgen not putting patients first

Regeneron CEO Len Schleifer ripped into Amgen for its insistence on blocking sales of a rival cholesterol drug during the appeals process in a patent infringement case.

Read More »

Page 1 of 3212345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2017 Focus: Top 10 Pipelines, Agenda 2017 and more!

Subscribe

Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation